December 2023 FDA Recall Liothyronine Sodium by Sun Pharmaceutical Industries Inc
D-0150-2024 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Sun Pharmaceutical Industries Inc on December 4, 2023 for the product Liothyronine Sodium. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0150-2024

Reason for Recall
Failed Impurities/Degradation Specifications
Initiated
12-04-2023
Reported
12-20-2023
Quantity
96,192 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
SUN PHARMACEUTICAL INDUSTRIES INC
Liothyronine Sodium Tablets, USP 5 mcg, 100-count bottle, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India. NDC 62756-589-88

Batch or Lot Expiration Information

Lot# Lot DND0059A Expires 12/2023 Lot DND0060A Expires 12/2023 Lot DND0061A Expires 12/2023 Lot DND0062A Expires 01/2024 Lot DND0063A Expires 01/2024 Lot DND0064A Expires 01/2024 Lot DND0065A Expires 01/2024 Lot DND0180A Expires 01/2024 Lot DND0181A Expires 01/2024 Lot DND0182A Expires 01/2024 Lot DND0183A Expires 01/2024 Lot DND0184A Expires 01/2024 Lot DND0597A Expires 02/2024